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410Background: ESPRIT is an ongoing, 10-year, observational registry, evaluating long-term safety and
effectiveness of adalimumab treatment in routine clinical practice for patients with moderate to severe,
chronic plaque psoriasis.Objectives: Initial 5-year results are reported.Methods: Two populations were analyzed: the ‘‘all-treated’’ population received 1 or more adalimumab
doses in registry, continuing adalimumab treatment froma current prescriptionor previous studyparticipation,
and included the ‘‘new-prescription’’ population initiating adalimumab 4 weeks or earlier preregistry entry.Results: Data were collected from September 26, 2008, through November 30, 2013, for all-treated
(n = 6059), which included new-prescription (n = 2580, 42.6%); median registry exposure was 765 and
677 days, respectively. In all-treated, rate (events per 100 patient-years of total adalimumab exposure [E/
100PY]) of serious treatment-emergent adverse events (inside or outside of the registry) was 4.3 E/100PY,
serious infection 1.0 E/100PY, malignancies 0.9 E/100PY (nonmelanoma skin cancers 0.6 E/100PY;
melanomas \0.1 E/100PY). Standardized mortality ratio was 0.30 (95% confidence interval 0.19-0.44).
Physician Global Assessment clear or minimal (effectiveness parameter) was achieved by 57.0% at
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Menter et al 411Limitations: Observational data are subject to outcome-reporting bias.Conclusion: No new safety signals were observed with adalimumab treatment during this initial 5-year
registry review. Observed number of deaths was below expected. As-observed effectiveness remained
stable through 60 months. ( J Am Acad Dermatol 2015;73:410-9.)
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d Adalimumab has an established safety
profile in psoriasis and across different
indications.
d Findings from the first 5 years of ESPRIT,
a prospective registry of patients with
psoriasis treated with adalimumab per
local label in daily practice, support the
safety of long-term treatment.
d Results afford opportunities for clinician/
patient interactions on treatment safety.Psoriasis is a chronic, sys-
temic, immune-mediated dis-
ease, associatedwithmultiple
comorbidities,1,2 including
risk factors for cardiovascular
disease and metabolic
syndrome (hypertension, dia-
betes, hyperlipidemia, and
obesity) especially in patients
with severe psoriasis,3-6 with
an increased risk for myocar-
dial infarction (MI)7 and pso-
riatic arthritis.1,2 Long-term
efficacy and/or safety of
antietumor necrosis factor-
alfa agents, including adali-
mumab,has beendemonstrated inmoderate to severe
psoriasis for up to 5 years in clinical trials and
observational registries,8-13 and in a database analysis
across multiple indications of adalimumab (including
psoriasis) in patients with up to 12 years of adalimu-
mab exposure.14 ESPRIT is an ongoing, multicenter,
postmarketing, 10-year, international, observational
registry (NCT00799877)with the objective of prospec-
tively evaluating long-term safety and effectiveness of
adalimumab in patients treated for chronic psoriasis
per local product label in routine clinical practice,who
are candidates for systemic therapy or phototherapy.
Enrollment completed November 8, 2012. The
objective of this prespecified analysis was to
determine the cumulative, long-term safety and
effectiveness of adalimumab over the first 5-year
period.
METHODS
Eligible patients were adults ($18 years of age)
with chronic plaque psoriasis who had been
prescribed adalimumab according to local product
labeling, signed an informed consent before
collection of registry-related data, and met 1 of the
following entry criteria: (1) initiated adalimumab
within 4 weeks before entry into the registry; or (2)
previously initiated adalimumab and were not off
drug more than 70 consecutive days, or previously
participated in an adalimumab clinical trial (‘‘feeder
trial’’) sponsored by AbbVie Inc, North Chicago, IL,
and were not off drug more than 70 consecutive daysafter study completion. An
independent or central ethics
committee, or central or local
institutional review board,
approved the study. Two
registry populations are
identified: the all-treated
population received at least
1 dose of adalimumab during
the registry; the new-
prescription population, a
subgroup of the all-treated
population, received the
initial (first-ever) dose within
4 weeks before registry
enrollment. The registrydesign and maximum follow-up schedule are illus-
trated in Fig 1. Patients are encouraged to remain in
the registry but can discontinue at any time. Those
who discontinue adalimumab are encouraged to
continue in the registry to allow complete collection
of safety information.
Adalimumab is dosed according to the local
product label. Patients are allowed concomitant
therapy for psoriasis in accordance with their
physician’s usual and customary medical practice;
however, concurrent use of anakinra, abatacept, or
other biologic agents is prohibited. Patients are
allowed to continue in the registry if they were being
treated with a systemic psoriasis therapy other than
adalimumab. For patients who initiated adalimumab
therapy before entering the registry or who
continued therapy after completing a feeder trial,
the full period between initial dose or the end of the
previous study and the start of the registry is
considered as exposure time since patients received
continuous therapy per protocol inclusion criteria
(ie, no more than 70 days off drug).
In this analysis, safety was evaluated throughout
the registry for both populations by analysis of
adverse events (AEs) that were serious, of special
interest, spontaneously reported, or led to registry or
registry drug discontinuation. Special-interest AEs
were defined as those of most concern during
adalimumab treatment or those with higher rates
compared with placebo in clinical psoriasis
trials, and were analyzed in the first 5 years of the
Abbreviations used:
AE: adverse event
E/100PY: events per 100 patient-years of total
adalimumab exposure
MI: myocardial infarction
PGA: Physician Global Assessment
PY: patient-years
TB: tuberculosis
TEAE: treatment-emergent adverse event
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cardiovascular-related, infection-related, and malig-
nancies. The focus of this report is on treatment-
emergent AEs (TEAEs), which were events occurring
from initial adalimumab dose through 70 days
after last registry dose, excluding events during
treatment interruptions. These were analyzed for the
all-treated population and for subgroupswith different
durations of total exposure to adalimumab inside or
outside of the registry. Treatment effectiveness was
measured by achievement of the Physician Global
Assessment (PGA) of 0 (clear) or 1 (minimal) on a 6-Fig 1. Registry design. Feeder trials included M02
(phase II, n = 1, June 2003), M03-658 (open-labe
included the REVEAL, CHAMPION, M02-538 tri
counted separately from the OLE’s 195 patients), M
2004), M04-716 (phase III CHAMPION, n = 2, July
M10-060 (BELIEVE, n = 75, November 2007), W1
2007), M10-238 (phase III PROGRESS, n = 25, Jan
n = 23, August 2008). *Patients are followed up at r
by routine clinical practice or as recommended b
followed up for up to 10 years, including patients w
of registry participation, during regular office visit
national guidelines. Registry visits are conducted
then every 6 months for up to 10 years. yStudy stpoint severity scale. Statistical methods for safety
and efficacy evaluations are provided in the
‘‘Supplementary information’’ section available at
http://www.jaad.org.RESULTS
Patients
This analysis collected data from September 26,
2008, through November 30, 2013, for 6059 patients
in the all-treated population, including 2580 (42.6%)
in the new-prescription population. Patients were
enrolled in 13 countries. The United States and
Canada had a combined enrollment of 5059 (83.5%)
patients (Table SI; available at http://www.jaad.org).
Upon enrollment completion (November 8, 2012),
6.4% had enrolled from a feeder trial and 51.0% had
received their initial dose of adalimumab outside of a
feeder trial and more than 4 weeks before entering
the registry (Fig 1).
At enrollment (baseline), demographics were
generally comparable between the 2 populations
(Table I). More new-prescription patients had severe-570 (phase III, n = 1, June 2003), M02-538
l extension trial [OLE], n = 195, May 2004;
als for which the number of patients was
03-656 (phase III REVEAL, n = 3, December
2005), M06-808 (phase III, n = 1, June 2006),
0-151 (phase III PRIDE, n = 62, September
uary 2008), and M10-405 (phase IV REACH,
egular office visits, at intervals as determined
y national guidelines. Enrolled patients are
ho discontinue adalimumab before 10 years
s that are determined by routine practice or
initially at 3 and 6 months postenrollment,
art dates are shown.
Table I. Patient demographics, characteristics, and
medical history at entry into the registry
All-treated
population,
N = 6059
n (%)
New-prescription
population,
N = 2580
n (%)
Sex
Male 3493 (57.6) 1395 (54.1)
Female 2566 (42.4) 1185 (45.9)
Race
White 5234 (87.3) 2230 (87.1)
Black 178 (3.0) 67 (2.6)
Asian 253 (4.2) 105 (4.1)
Other* 331 (5.5) 158 (6.1)
Disease characteristics
Psoriatic arthritis y 862 (33.9)
Family history of psoriasis y 1068 (42.0)
PGA (0-5)z
Clear (0) 556 (11.5) 43 (2.0)
Minimal (1) 899 (18.7) 104 (4.9)
Mild (2) 905 (18.8) 251 (11.8)
Moderate (3) 1456 (30.2) 920 (43.4)
Severe (4) 813 (16.9) 649 (30.6)
Very severe (5) 185 (3.8) 154 (7.3)
Median (range) Median (range)
Age, y 47.0 (18-94) 46.0 (18-91)
Weight, kg 87.0 (41-252)
n = 5904
87.0 (41-218)
n = 2506
BMI, kg/m2 29.4 (16-76.8)
n = 5883
29.4 (16-69.9)
n = 2498
Duration of psoriasis,x y y 13.4 (0-68)
n = 2543
Medical history{ in $5% of
patients and other history of
interest
New-prescription
population
N = 2580, n (%)
Cardiovascular-related
Hypertension 567 (22.0)
Coronary artery disease 48 (1.9)
MI 30 (1.2)
Cardiac arrhythmia 21 (0.8)
Angina 19 (0.7)
CHF 8 (0.3)
CVA 6 (0.2)
Gastrointestinal
Gastroesophageal reflux
disease
162 (6.3)
Inflammatory bowel
disease
14 (0.5)
Metabolic
Hyperlipidemia 295 (11.4)
Diabetes mellitus 244 (9.5)
Hypothyroidism 140 (5.4)
Obesity 46 (1.8)
Infection-related
TB 27 (1.0)
Malignancy
Cancer 23 (0.9)
Continued
Table I. Cont’d
Medical history{ in $5% of
patients and other history of
interest
New-prescription
population
N = 2580, n (%)
Neurologic and psychiatric
Depression 245 (9.5)
Anxiety disorder 132 (5.1)
BMI, Body mass index; CHF, congestive heart failure; CVA,
cerebrovascular accident; MI, myocardial infarction; PGA,
Physician Global Assessment; TB, tuberculosis.
*Includes American Indian/Alaska Native (all-treated, 0.3%;
new-prescription, 0.3%), native Hawaiian or other Pacific Islander
(all-treated, 0.7%; new-prescription, 0.9%), multiple races
(all-treated, 0.4%; new-prescription, 0.5%), other (all-treated,
4.2%; new-prescription, 4.5%). Missing (all-treated, n = 63;
new-prescription, n = 20).
yNot analyzed because not all data were captured in the registry
database.
zMany patients received adalimumab before entering the registry,
demonstrated by the number of patients entering the registry
with a PGA 0 or 1. Missing data (all-treated, n = 1245;
new-prescription, n = 459).
xCalculated from start of registry.
{Medical history at enrollment was summarized only for the
new-prescription population.
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population). More all-treated patients had baseline
PGA of 0 or 1 (30.2% vs 6.9% new-prescription
population), most likely occurring because many of
the all-treated population received adalimumab
longer than 4 weeks before registry entry. Baseline
comorbidities for the new-prescription population
included risk factors for cardiovascular disease
(Table I).
Patients were observed for 17,739.8 patient-years
(PY) (first to last day in the registry), and exposed to
adalimumab during the registry for 13,639.0 PY. Total
patient exposure was 19,242.8 PY. Exposure to
adalimumab during and outside of the registry is
shown in Table II. Registry discontinuation rates
were 10.6% and 13.1% for the all-treated and
new-prescription populations, respectively (Table
SII; available at http://www.jaad.org). At the time
of data cutoff for the registry’s first 5 years, 76.5% and
69.2% of the all-treated and new-prescription
populations, respectively, had not permanently
discontinued adalimumab. Of patients continuing
in the registry, 85.6% and 79.6% in the all-treated and
new-prescription populations, respectively, were
continuing adalimumab. The most frequent reason
for discontinuation from the registry was lost to
follow-up (3.6% and 4.5% for all-treated and new-
prescription populations, respectively) (Table SII).
Time to discontinuation of adalimumab within the
registry is illustrated in Fig 2, A. Patients were eligible
to reinitiate adalimumab after any interruption.
Table II. Duration of patient exposure to adalimumab in ESPRIT
Subgroups with different durations of total exposure to adalimumab, N
#1 y [1-3 y [3-5 y [5 y
Total adalimumab exposure (during or outside of registry)*
All-treated population,y N = 6059 953 2029 2109 968
New-prescription population,z N = 2580 724 1037 815 4
Adalimumab exposure during registryx
All-treated population,y N = 6059 1301 2617 2136 5
New-prescription population,z N = 2580 726 1037 813 4
*Calculated as the date of the last dose minus the date of the initial dose plus 14 d, minus the total days of treatment interruptions during
the registry.
yIncluded 388 patients from previous AbbVie clinical trials and 3091 with existing prescriptions.
zSubgroup of all-treated population who entered the registry with new prescriptions.
xCalculated as the date of the last dose minus the date of the first dose in the registry plus 14 d, minus the total days of treatment
interruptions during the registry.
Table III. Incidence rates for treatment-emergent adverse events (all-treated population)
Subgroups with different durations of total
exposure to adalimumab, events (E/100PY)
Overall, events (E/100PY)#1 y [1-3 y [3-5 y [5 y
PY = 493.4
N = 953
PY = 3999.9
N = 2029
PY = 8506.6
N = 2109
PY = 6242.9
N = 968
PY = 19,242.8
N = 6059
TEAEs
Any TEAE 280 (56.7) 612 (15.3) 988 (11.6) 2393 (38.3) 4273 (22.2)
TEAE leading to death 8 (1.6) 10 (0.3) 7 (\0.1) 2 (\0.1) 27 (0.1)
Serious TEAEs overview
Any serious TEAE 116 (23.5) 219 (5.5) 325 (3.8) 167 (2.7) 827 (4.3)
Any serious infection 30 (6.1) 58 (1.5) 64 (0.8) 36 (0.6) 188 (1.0)
Serious TEAEs by $20 events overall
Cellulitis* 8 (1.6) 9 (0.2) 4 (\0.1) 5 (\0.1) 26 (0.1)
Pneumoniay 4 (0.8) 5 (0.1) 9 (0.1) 6 (0.1) 24 (0.1)
MIz 5 (1.0) 4 (0.1) 8 (0.1) 3 (\0.1) 20 (0.1)
SCCx 0 2 (0.1) 11 (0.1) 7 (0.1) 20 (0.1)
TEAEs leading to registry discontinuation
Any TEAE 34 (6.9) 19 (0.5) 17 (0.2) 4 (\0.1) 74 (0.4)
TEAEs by $5 events overall
MI 1 (0.2) 2 (\0.1) 1 (\0.1) 1 (\0.1) 5 (\0.1)
TEAEs leading to registry drug discontinuation
Any TEAE{ 149 (30.2) 125 (3.1) 100 (1.2) 14 (0.2) 388 (2.0)
TEAEs by $5 events overall
MIz 3 (0.6) 3 (\0.1) 1 (\0.1) 1 (\0.1) 8 (\0.1)
Drug hypersensitivity 4 (0.8) 0 1 (\0.1) 0 5 (\0.1)
Bronchitis 1 (0.2) 5 (0.1) 1 (\0.1) 0 7 (\0.1)
Cellulitisk 3 (0.6) 3 (\0.1) 1 (\0.1) 0 7 (\0.1)
Pneumonia# 2 (0.4) 5 (0.1) 4 (\0.1) 0 11 (0.1)
Arthralgia 2 (0.4) 2 (\0.1) 1 (\0.1) 0 5 (\0.1)
Headache 4 (0.8) 2 (\0.1) 0 0 6 (\0.1)
Psoriasis 13 (2.6) 17 (0.4) 8 (\0.1) 1 (\0.1) 39 (0.2)
Some patients were exposed to adalimumab up to 6 y before entering the registry (Fig 1).
E/100PY, Events per 100 patient-years of total adalimumab exposure; MI, myocardial infarction; PY, patient-year; SCC, squamous cell
carcinoma; TEAE, treatment-emergent adverse event.
*Includes cellulitis, and anorectal, staphylococcal, external-ear, infusion-site, and periorbital cellulitis.
yIncludes pneumonia, and atypical, lobar, legionella, and aspiration pneumonias.
zIncludes MI and acute MI.
xIncludes SCC and SCC of skin.
{Events not coded (n = 6).
kIncludes cellulitis and anorectal cellulitis.
#Includes pneumonia, pneumonia mycoplasmal, atypical pneumonia, and pneumonia aspiration.
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Table IV. Incidence rates for treatment-emergent adverse events of special interest (all-treated population)
TEAEs of special interest
Subgroups with different durations
of total exposure to adalimumab, events (E/100PY)
Overall, events (E/100PY)#1 y [1-3 y [3-5 y [5 y
PY = 493.4
N = 953
PY = 3999.9
N = 2029
PY = 8506.6
N = 2109
PY = 6242.9
N = 968
PY = 19,242.8
N = 6059
Cardiovascular-related
CVA 2 (0.4) 5 (0.1) 10 (0.1) 9 (0.1) 26 (0.1)
CHF 2 (0.4) 3 (\0.1) 6 (\0.1) 1 (\0.1) 12 (\0.1)
MI 5 (1.0) 4 (0.1) 8 (\0.1) 3 (\0.1) 20 (0.1)
Malignancies
Malignancy 15 (3.0) 33 (0.8) 76 (0.9) 54 (0.9) 178 (0.9)
Lymphoma 0 0 2 (\0.1) 0 2 (\0.1)
HSTCL 0 0 0 0 0
NMSC 4 (0.8) 15 (0.4) 50 (0.6) 43 (0.7) 112 (0.6)
Leukemia 0 0 0 0 0
Melanoma 4 (0.8) 1 (\0.1) 3 (\0.1) 2 (\0.1) 10 (\0.1)
Malignancy, other* 7 (1.4) 17 (0.4) 21 (0.2) 10 (0.2) 55 (0.3)
Infection-related
Infection 69 (14.0) 215 (5.4) 337 (4.0) 864 (13.8) 1485 (7.7)
Oral candidiasis 0 5 (0.1) 0 3 (\0.1) 8 (\0.1)
Opportunistic infectiony 0 0 1 (\0.1) 0 1 (\0.1)
Active TB 0 2 (\0.1) 1 (\0.1) 0 3 (\0.1)
Latent TB 1 (0.2) 7 (0.2) 4 (\0.1) 3 (\0.1) 15 (\0.1)
Some patients were exposed to adalimumab up to 6 y before entering the registry (Fig 1).
CHF, Congestive heart failure; CVA, cerebrovascular accident; E/100PY, events per 100 patient-years of total adalimumab exposure;
HSTCL, hepatosplenic T-cell lymphoma; MI, myocardial infarction; NMSC, nonmelanoma skin cancer; PY, patient-year; TB, tuberculosis;
TEAE, treatment-emergent adverse event.
*Excluding melanoma, lymphoma, HSTCL, NMSC, or leukemia.
yExcluding oral candidiasis and TB.
J AM ACAD DERMATOL
VOLUME 73, NUMBER 3
Menter et al 415Safety
This analysis focusses on TEAEs for the all-treated
population. Rates of observational AEs and registry
TEAEs of special interest are provided in the
‘‘Supplemental information’’ section and Table SIII
(available at http://www.jaad.org).
The rate of serious TEAEs was 4.3 events per 100
PY of total adalimumab exposure (E/100PY) (Table
III); the most common was infection (1.0 E/100PY),
and no patterns across any exposure categories were
identified. The rates for TEAEs leading to discontin-
uation from the registry or from registry drug overall
were 0.4 E/100PY and 2.0 E/100PY, respectively
(Table III). Rates of AEs leading to registry and
registry drug discontinuation decreased across
subgroups with different duration of total exposure
to adalimumab treatment (Table III). The rate of
events leading to death regardless of causality was
0.1 E/100PY (Table SIV; available at http://www.
jaad.org). The most common event leading to death
was MI (\0.1 E/100PY).
Cardiovascular-related TEAEs of special interest
included cerebrovascular accident (0.1 E/100PY),
MI (0.1 E/100PY), and congestive heart failure
(\0.1 E/100PY) (Table IV). The overall incidencerate for malignancy was 0.9 E/100PY (\0.1 E/100PY
for each of melanoma and lymphoma, and
0.6 E/100PY for nonmelanoma skin cancer) and
0.3 E/100PY for other malignancies (Table IV). The
overall incidence rate of infections was 7.7 E/100PY
(\0.1 E/100PY for each of oral candidiasis, active
tuberculosis [TB], latent TB, and opportunistic
infection other than oral candidiasis or TB)
(Table IV). The times to the first occurrence of
TEAEs of special interest are illustrated in Fig 2, B.
The standardized mortality ratio was similar for
the all-treated (0.30 [95% confidence interval
0.19-0.44]) and the new-prescription (0.33 [95%
confidence interval 0.17-0.60]) populations (Fig 3).
The number of observed deaths was below
the expected age-, sex-, and country-matched
population.
Effectiveness
In both populations, PGA 0 or 1 was achieved by
over 50%ofpatients at years 1 and2, andgenerally over
60% at years 3 to 5 of their registry participation (Fig 4,
A). The percentage of patients within each group
achieving PGA 0 or 1 increased across the 5 years,
with a slight decrease at year 4 in the new-prescription
Fig 2. Kaplan-Meier plots: continuation on registry drug (A) and time to occurrence of
first treatment-emergent adverse event (TEAE ) of special interest (all-treated population) (B).
CVA, Cerebrovascular accident; MI, myocardial infarction; NMSC, nonmelanoma skin cancer;
TB, tuberculosis.
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population with or without psoriatic arthritis achieved
PGA 0 or 1 for psoriasis at years 1 to 4 (Fig 4, B).
DISCUSSION
In this analysis of the first 5 years of the ESPRIT
registry, psoriasis-related comorbidities observed at
baseline included inflammatory bowel disease,
psoriatic arthritis, and other cardiovascular-related
conditions including cerebrovascular accident,
congestive heart failure, and MI, plus risk factors for
cardiovascular disease (hypertension, diabetes, and
hyperlipidemia).
Safety
Observed AEs in the first 5 years of this registry are
consistent with the adalimumab safety profile and nonew safety signals were observed. Historically,
AEs of special interest after treatment with
antietumor necrosis factor agents, include serious
infections, malignancies, reactivation of TB,14-20 and
development or worsening of congestive heart
failure.21,22 Conflicting reports make any risk of
lymphoma development difficult to assess as this
risk has also been associated with pre-existing
psoriasis and systemic inflammation, ie, up to a
2-fold increased risk in the psoriatic population at
baseline.15,23
Across the subgroups of patients with different
durations of total exposure to adalimumab in this
analysis, incidence rates of any TEAE and infection
decreased as time of total exposure to adalimumab
increased up to 5 years. The subgroupwithmore than
5 years of total adalimumab exposurewasmore likely
Fig 3. Standardized mortality, overall and by sex. PY, Patient-years of exposure.
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exposure to adalimumab. As total exposure to
adalimumab increased, rates also generally decreased
after 1 year of total exposure for the TEAEs of special
interest and remained stable thereafter, except rates
for malignancies, which slightly increased after
3 years, and rates for nonmelanoma skin cancer,
which generally increased slightly, although did not
reach the level of the less than or equal to 1 year
category rate. Incidence rates for any TEAE that led to
registry or registry drug discontinuation decreased as
total exposure increased. Generally, decreased rates
of AEs with increased exposure to adalimumab were
also reported in clinical trial populations treated
long-term.10,11,14
In this analysis, rates of any serious TEAE and
serious TEAEs of special interest were low, and rates
of serious TEAEs and serious infections decreased
with increasing adalimumab exposure. In another
observational registry of patients with psoriasis
treated with an antietumor necrosis factor agent,
the cumulative incidence proportions of serious
TEAEs and serious infections increased with
increasing exposure to drug over 3 years of
the registry.24 In that registry, rates of serious
AEs (5.18 E/100PY) and serious infections
(1.46 E/100PY) were similar to rates observed in the
current analysis. The number of observed deaths in
the current analysis (all-treatedpopulation, 0.8%)was
lower than would be expected in the general
population, and deaths caused by TEAEs
(0.1 E/100PY) declined as exposure to adalimumab
increased.Effectiveness
Adalimumab treatment for psoriasis showed
increasing observed effectiveness across the first
5 years of ESPRIT, even though at entry into the
registry, some patients had received varying durations
of adalimumab treatment and therefore,mayhavehad
clear to minimal disease severity at baseline. Long-
term efficacy results may be affected by patient
discontinuation that was due to poor efficacy. The
majority of patients continuing in the registry after
the first 5 years continued treatment with adalimu-
mab. Patients with psoriatic arthritis experienced a
similar degree of increasing effectiveness for psoriasis
across the first 5 years; however, because psoriatic
arthritis was patient-reported and not necessarily
diagnosed previously by a rheumatologist, this result
should be interpreted with caution.
Population differences
Despite the fact that the all-treated population
likely had a longer exposure to adalimumab at entry
to the registry compared with the new-prescription
population, and that the portion of this group
originating from a feeder trial may have had to meet
more feeder-trial entry requirements than patients
entering the registry outside of a feeder trial, the
adalimumab safety and treatment-effectiveness
profiles were similar for both populations. In
addition, similar percentages of patients in both
populations stayed in the registry and on adalimumab
during the registry’s first 5 years. These important
observations suggest that the effectiveness and safety
profiles of adalimumab are similar for patients
Fig 4. Proportion of observed (not necessarily on drug at the time of this assessment) patients
achieving Physician Global Assessment 0 or 1: all-treated and new-prescription populations (A)
and new-prescription population (B) by presence or absence of psoriatic arthritis (PsA).
n, Number of patients with Physician Global Assessment 0 or 1 at the respective visit;
N, number of patients with data at the respective visit.
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controlled, clinical trials.
Limitations
Observational data are subject to outcome-
reporting bias. At entry into the registry, somepatients
were adalimumab-na€ıve. For patients with long-term
adalimumab treatment before registry enrollment,the total exposure-adjusted incidence rate of TEAEs
may be underestimated, and lower PGA scores at
registry entry may have affected efficacy results.Conclusions
During the first 5 years of the ongoing, postmar-
keting ESPRIT registry, adalimumab continued to be
J AM ACAD DERMATOL
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Menter et al 419well tolerated in the vast majority of this large
population of adults with chronic plaque
psoriasis, and no new safety signals were identified.
Safety was comparable with previous adalimumab
clinical trials and postmarketing surveillance. Based
on this analysis, the known safety profile of
adalimumab remains unchanged. Adalimumab
demonstrated continued effectiveness over the
registry’s first 5 years.
The authors would like to acknowledge the registry
investigators for their contributions to this registry, and
Jody Bennett, DC, employee of AbbVie, for medical writing
contributions to this manuscript.
REFERENCES
1. Gulliver W. Long-term prognosis in patients with psoriasis. Br J
Dermatol. 2008;159(Suppl 2):2-9.
2. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis
Foundation clinical consensus on psoriasis comorbidities and
recommendations for screening. J Am Acad Dermatol. 2008;58:
1031-1042.
3. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH.
Incidence of cardiovascular disease in individuals with
psoriasis: a systematic review and meta-analysis. J Invest
Dermatol. 2013;133:2340-2346.
4. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the
prevalence of major medical comorbidity: a population-based
study. JAMA Dermatol. 2013;149:1173-1179.
5. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,
Gelfand JM. Prevalence of cardiovascular risk factors in
patients with psoriasis. J Am Acad Dermatol. 2006;55:829-835.
6. Gulliver WP, Macdonald D, Gladney N, Alaghehbandan R,
Rahman P, Adam Baker K. Long-term prognosis and
comorbidities associated with psoriasis in the Newfoundland
and Labrador founder population. J Cutan Med Surg. 2011;15:
37-47.
7. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ,
Troxel AB. Risk of myocardial infarction in patients with
psoriasis. JAMA. 2006;296:1735-1741.
8. Shear NH, Hartmann M, Toledo-Bahena M, et al. Long-term
efficacy and safety of infliximab maintenance therapy in
patients with plaque-type psoriasis in real-world practice. Br
J Dermatol. 2014;171:631-641.
9. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and
efficacy of 50 mg of etanercept twice weekly in patients with
psoriasis. Arch Dermatol. 2007;143:719-726.10. Leonardi C, Papp K, Strober B, et al. The long-term safety of
adalimumab treatment in moderate to severe psoriasis: a
comprehensive analysis of all adalimumab exposure in all
clinical trials. Am J Clin Dermatol. 2011;12:321-337.
11. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH.
Long-term efficacy and safety of adalimumab in patients
with moderate to severe psoriasis treated continuously over 3
years: results from an open-label extension study for patients
from REVEAL. J Am Acad Dermatol. 2012;66:241-251.
12. Kimball AB, Rothman KJ, Kricorian G, et al. OBSERVE-5:
observational postmarketing safety surveillance registry of
etanercept for the treatment of psoriasis final 5-year results. J
Am Acad Dermatol. 2014;72:115-122.
13. Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on
cardiovascular co-morbidities: focus on TNF inhibitors. Am J
Clin Dermatol. 2014;15:45-50.
14. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ,
Lacerda AP. Adalimumab: long-term safety in 23 458 patients
from global clinical trials in rheumatoid arthritis, juvenile
idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis,
psoriasis and Crohn’s disease. Annals Rheum Diseases. 2013;72:
517-524.
15. Cordoro KM, Feldman SR. TNF-alpha inhibitors in
dermatology. Skin Therapy Letter. 2007;12:4-6.
16. Humira [package insert]. North Chicago, IL, USA: AbbVie Inc;
2013.
17. Enbrel [package insert]. Thousand Oaks, CA: Amgen; 2013.
18. Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc;
2013.
19. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor
necrosis factor antagonist mechanisms of action: a compre-
hensive review. Pharmacol & Therapeutics. 2008;117:244-279.
20. Semble AL, Davis SA, Feldman SR. Safety and tolerability of
tumor necrosis factor-alpha inhibitors in psoriasis: a narrative
review. Am J Clin Dermatol. 2014;15:37-43.
21. Jackson JM. TNF-alpha inhibitors. Derm Ther. 2007;20:251-264.
22. Scheinfeld N. A comprehensive review and evaluation of the
side effects of the tumor necrosis factor alpha blockers
etanercept, infliximab and adalimumab. J Derm Treat. 2004;
15:280-294.
23. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies
associated with tumor necrosis factor inhibitors in registries
and prospective observational studies: a systematic review
and meta-analysis. Annals Rheum Diseases. 2011;70:
1895-1904.
24. Kimball AB, Pariser D, Yamauchi PS, et al. OBSERVE-5 interim
analysis: an observational postmarketing safety registry of
etanercept for the treatment of psoriasis. J Am Acad Dermatol.
2013;68:756-764.
J AM ACAD DERMATOL
SEPTEMBER 2015
419.e1 Menter et alSUPPLEMENTAL INFORMATION
Methods
Physician Global Assessment (PGA) 0 indicates
clear or no plaque elevation or scaling accompanied
by erythema of diffuse pink/red coloration.
Physician Global Assessment 1 indicates minimal or
plaque elevation possible but difficult to ascertain,
scaling consisting of surface dryness and some white
coloration; up to moderate erythema (up to definite
red coloration).Statistical analysis
As this was an analysis of a postmarketing
observational registry, no missing data were
replaced and outliers are included in the analyses.
The observational period was the number of days
from registry enrollment to last day in the registry.
Descriptive statistics are presented for demographic
and baseline characteristics. Effectiveness was
measured by the proportion of patients achieving
PGA 0 or 1, analyzed as observed during registry
participation by descriptive statistics (patients were
not necessarily taking adalimumab at the time of an
assessment; they may have been taking a topical or a
different systemic treatment or no treatment at all).
Adverse events (AEs) occurring between the
period of a patient’s first-ever adalimumab dose or
the end of a feeder trial and the start of the registry
were collected retroactively. Incidence rates of AEs
are reported as events per 100 patient-years of total
adalimumab exposure (E/100PY). A serious AE
was any event that was fatal, was life-threatening,
required hospital admission or prolonged
hospitalization, was a congenital anomaly, resulted
in a persistent or significant disability, required
medical/surgical intervention to prevent a serious
outcome, or was a spontaneous or an elective
abortion. Serious AEs of special interest and AEs
leading to adalimumab discontinuation were
analyzed as observational AEs, treatment-emergent
AEs (TEAEs), and registry TEAEs. Observational AEs
and registry TEAEs are described below.
The standardized mortality ratio (ratio of
observed to expected registry treatment-emergent
deaths) was calculated using the most recent
country-specific World Health Organization mortal-
ity through 2006. A ratio of less than 1.0 indicates an
observed death rate below expected in an age-, sex-,
and country-matched population. Confidence
intervals were calculated using Byar approximation.Patient exposure to adalimumab
Total exposure to adalimumab was calculated as
the date of last adalimumab dose minus date of initialadalimumab dose plus 14 days minus total days of
treatment interruption during the registry. For TEAEs
by exposure category, the TEAE did not occur at
these time points. They represent TEAEs within or
outside of the registry reported by patients who had
been exposed to adalimumab for the time periods
indicated by the exposure category. Total exposure
is based on the initial dose, whether occurring in or
outside of the registry, and was analyzed in
increments up to 1, more than 1 to 3, more than 3
to 5, and more than 5 years. Registry exposure was
calculated as the date of the last adalimumab dose
minus the date of the first adalimumab dose in
the registry plus 14 days minus the total days of
treatment interruption. The time to a patient’s
discontinuation of adalimumab was analyzed using
Kaplan-Meier methodology.
The median duration of total exposure was
1118 days (range 14-4352) and 680 days (range
14-1892) for the all-treated and new-prescription
populations, respectively; median exposure in
registry was 765 days (range 14-1892) and 677 days
(range 14-1892) for the all-treated and new-
prescription populations, respectively; and during
feeder trials was 953.0 days (N = 377). Approximately
50% (56.7% and 47.6% all-treated and new-
prescription populations, respectively) had neither
permanently stopped nor interrupted adalimumab
treatment for more than 70 days (Table SII).
Time to discontinuation
Time to registry discontinuation was defined as
the last contact minus first day in the registry plus 1 if
the patient discontinued from the registry, otherwise
the patient was censored at the cutoff date plus 1 day.
Time to registry drug discontinuation was defined as
the date of last adalimumab dose in the registry
minus the first adalimumab dose in the registry plus 1
minus total days of treatment interruptions during
the registry if the patient permanently discontinued
the registry or the registry drug. If still on drug in the
registry, the patient was censored at the cutoff date
plus 1 day, adjusting the time since the first adali-
mumab dose in the registry for total days of treatment
interruptions during the registry.
Time to first TEAE
Time to first TEAE (or registry TEAE) was defined
as the date of first occurrence of the event minus the
initial adalimumab dose (or first adalimumab dose in
the registry), plus 1 minus the total number of days of
treatment interruptions during the registry if the
patient had an event. If the patient permanently
discontinued the registry or registry drug without
having a TEAE, the patient was censored at the last
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since the initial adalimumab dose (or first adalimu-
mab dose in the registry) for total days of treatment
interruptions during the registry. If the patient was
still on drug in the registry without a TEAE, the
patient was censored at the cutoff date plus 1 day,
adjusting the time since the initial adalimumab dose
(or first adalimumab dose in the registry) for total
days of treatment interruptions during the registry.
Observational AEs and registry TEAEs
See Table SIII. Observational AEs were events
occurring from first registry day through last contact
irrespective of treatment duration, andwere analyzed
for the all-treated and new-prescription populations.
The incidence rate of the all-treated population with
serious AEs was 5.5 E/100PY of observation, serious
infections 1.2 E/100PY, and AEs leading to registry
drug discontinuation 2.2 E/100PY. Incidence rates forthe new-prescription population were 5.4 E/100PY
for serious AEs, 1.2 E/100PY for serious infections,
and 2.5 E/100PY for AEs leading to registry drug
discontinuation. Fifty deaths (observational) were
reported during the first 5 years of the registry; 2 of
these patients had not received a registry drug and
were not part of the all-treated population and 21
patients were of the new-prescription population.
For 6 patients, causes of death that were possibly or
probably related to adalimumab as determined by the
investigator were arrhythmia, staphylococcal
infection, staphylococcal sepsis, metastatic breast
cancer, squamous cell carcinoma of the lung, and
pneumonia aspiration.
Registry TEAEs were events occurring from first
registry adalimumab dose through 70 days after last
registry dose, excluding events during treatment
interruptions, and were analyzed for only the
all-treated population.
Table SI. Patient enrollment
Country
All-treated population,
N = 6059
n (%)
New-prescription
population,
N = 2580
n (%)
United States 4217 (69.6) 1969 (76.3)
Canada 842 (13.9) 144 (5.6)
Germany 158 (2.6) 87 (3.4)
France 132 (2.2) 64 (2.5)
Czech Republic 112 (1.8) 37 (1.4)
Greece 101 (1.7) 53 (2.1)
The Netherlands 104 (1.7) 41 (1.6)
Spain 106 (1.7) 91 (3.5)
United Kingdom 91 (1.5) 10 (0.4)
Austria 85 (1.4) 65 (2.5)
Denmark 87 (1.4) 14 (0.5)
Ireland 21 (0.3) 2 (\0.1)
Sweden 3 (\0.1) 3 (0.1)
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Table SII. Patient disposition
Reasons
Registry,* n (%) Registry drug,y n (%)
All-treated population
N = 6059
New-prescription population
N = 2580
All-treated population
N = 6059
New-prescription population
N = 2580
Continuing 5416 (89.4) 2243 (86.9) 4636 (76.5)z 1786 (69.2)z
Discontinued 643 (10.6) 337 (13.1) 780 (12.9)z 457 (17.7)z
No dose
discontinuation
or interruptionx
n/a n/a 3438 (56.7) 1228 (47.6)
Reasons for
discontinuation
AE 25 (0.4) 14 (0.5) 108 (1.8) 62 (2.4)
Lost to follow-up 221 (3.6) 117 (4.5) 146 (2.4) 89 (3.4)
Lack of efficacy 74 (1.2) 49 (1.9) 639 (10.5) 385 (14.9)
Withdrew consent 190 (3.1) 93 (3.6) 80 (1.3) 44 (1.7)
Other 83 (1.4) 38 (1.5) 268 (4.4) 150 (5.8)
Reasons for discontinuation are listed by $1% of the all-treated population across discontinuation categories.
AE, Adverse event; n/a, not applicable.
*Reasons in #1% of patients were AE, intolerance, patient death, serious AE, satisfactory improvement, noncompliant, pregnancy. Data
missing (all-treated population, n = 21; new-prescription population, n = 8).
yReasons in #1% of patients were intolerance, patient death, serious AE, required additional therapy. Data missing (all-treated population,
n = 149; new-prescription population, n = 56).
zAmong patients who have not yet discontinued the registry.
xPatients who neither permanently stopped adalimumab treatment nor interrupted adalimumab treatment for[70 d.
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Table SIII. Incidence rates of observational adverse events and registry treatment-emergent adverse events
Observational adverse events Registry TEAEs
All-treated population, N = 6059
PY of observation = 17,739.8
Events (E/100PY)
New-prescription population, N = 2580
PY of observation = 7777.6
Events (E/100PY)
All-treated population, N = 6059
PY of exposure = 13,639.0
Events (E/100PY)
Events of special interest
Any event* 2487 (14.0) 960 (12.3) 2046 (15.0)
Any event leading to registry
drug discontinuation
399 (2.2) 195 (2.5) 385 (2.8)
Any event leading to death 51 (0.3) 22 (0.3) 26 (0.2)
Cardiovascular-related
MI 22 (0.1) 10 (0.1) 17 (0.1)
CVA 31 (0.2) 16 (0.2) 23 (0.2)
CHF 16 (\0.1) 6 (\0.1) 12 (\0.1)
Malignancy-related
Malignancy 192 (1.1) 72 (0.9) 151 (1.1)
Lymphoma 3 (\0.1) 0 2 (\0.1)
HSTCL 0 0 0
NMSC 111 (0.6) 44 (0.6) 88 (0.6)
Leukemia 0 0 0
Melanoma 10 (\0.1) 4 (\0.1) 10 (\0.1)
Malignancy othery 69 (0.4) 24 (0.3) 52 (0.4)
Infection-related
Infections 817 (4.6) 278 (3.6) 700 (5.1)
Oral candidiasis 3 (\0.1) 1 (\0.1) 3 (\0.1)
Opportunistic infectionz 2 (\0.1) 0 1 (\0.1)
Latent TB 20 (0.1) 8 (0.1) 14 (0.1)
Active TB 3 (\0.1) 3 (\0.1) 3 (\0.1)
Serious events; $10 events in any
population
Any serious adverse eventx 977 (5.5) 418 (5.4) 758 (5.6)
Serious infection 212 (1.2) 90 (1.2) 175 (1.3)
Anginak 13 (\0.1) 9 (0.1) {
CHF 11 (\0.1) 4 (\0.1) {
MI# 22 (0.1) 10 (0.1) {
Cellulitis** 30 (0.2) 17 (0.2) {
Pneumoniayy 28 (0.2) 9 (0.1) {
Urinary tract infection 10 (\0.1) 3 (\0.1) {
Basal cell carcinoma 11 (\0.1) 3 (\0.1) {
SCCzz 18 (0.1) 11 (0.1) {
CVA 16 (\0.1) 9 (0.1) {
Depression 11 (\0.1) 5 (\0.1) {
Renal failurexx 11 (\0.1) 4 (\0.1) {
Psoriasis 15 (\0.1) 4 (\0.1) {
CHF, Congestive heart failure; CVA, cerebrovascular accident; E/100PY, events per 100 patient-years of observation/total adalimumab
exposure; HSTCL, hepatosplenic T-cell lymphoma; MI, myocardial infarction; NMSC, nonmelanoma skin cancer; PY, patient-year;
SCC, squamous cell carcinoma; TB, tuberculosis; TEAE, treatment-emergent adverse event.
*During the first 5 y of the registry, there was no reported reactivation of hepatitis B, HSTCL, leukemia, Stevens-Johnson syndrome, erythema
multiformeerelated adverse events, cutaneous vasculitis, amyotrophic lateral sclerosis, reversible posterior leukoencephalopathy syndrome,
progressive multifocal leukoencephalopathy, adalimumab administration medication error, Merkel cell carcinoma, Waldenstr€om
macroglobulinemia, or glioblastoma.
yMalignancy other than lymphoma, HSTCL, leukemia, NMSC, or melanoma.
zExcluding oral candidiasis and TB.
xEvents not coded: observational, all-treated population (n = 25); observational, new-prescription population (n = 14).
{Registry serious TEAEs were not summarized.
kIncludes angina unstable and angina pectoris.
#Includes MI and acute MI.
**Includes for all-treated: cellulitis, and anorectal, staphylococcal, external-ear, infusion-site, and periorbital cellulitis; and for
new-prescription: cellulitis, and staphylococcal and periorbital cellulitis.
yyIncludes for all-treated: pneumonia, and atypical, lobar, legionella, and aspiration pneumonias; and for new-prescription: pneumonia, and
staphylococcal and aspiration pneumonias.
zzIncludes SCC and SCC of skin.
xxIncludes renal failure and acute renal failure.
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Table SIV. All treatment-emergent adverse events leading to death (all-treated population)
Subgroups with different durations of total exposure
to adalimumab, events (E/100PY)
Overall events (E/100PY)#1 y [1-3 y [3-5 y [5 y
PY = 493.4
N = 953
PY = 3999.9
N = 2029
PY = 8506.6
N = 2109
PY = 6242.9
N = 968
PY = 19,242.8
N = 6059
Any TEAE leading to death* 8 (1.6) 10 (0.3) 7 (\0.1) 2 (\0.1) 27 (0.1)
Arrhythmia 0 1 (\0.1) 0 0 1 (\0.1)
Cardiac arrest 0 0 1 (\0.1) 0 1 (\0.1)
Cardiac failure acute 0 1 (\0.1) 0 0 1 (\0.1)
CHF 1 (0.2) 0 0 0 1 (\0.1)
MI 0 2 (\0.1) 1 (\0.1) 1 (\0.1) 4 (\0.1)
Deathy 2 (0.4) 1 (\0.1) 1 (\0.1) 1 (\0.1) 5 (\0.1)
Staphylococcal infection 1 (0.2) 0 0 0 1 (\0.1)
Staphylococcal sepsis 1 (0.2) 0 0 0 1 (\0.1)
Road traffic accident 1 (0.2) 0 0 0 1 (\0.1)
Breast cancer metastatic 0 1 (\0.1) 0 0 1 (\0.1)
Metastatic gastric cancer 0 0 1 (\0.1) 0 1 (\0.1)
Metastatic neoplasm 0 1 (\0.1) 0 0 1 (\0.1)
Papillary thyroid cancer 0 1 (\0.1) 0 0 1 (\0.1)
Sarcoma 0 1 (\0.1) 0 0 1 (\0.1)
Small cell lung cancer 0 0 1 (\0.1) 0 1 (\0.1)
Squamous cell carcinoma of lung 0 1 (\0.1) 0 0 1 (\0.1)
Subarachnoid hemorrhage 0 0 1 (\0.1) 0 1 (\0.1)
COPD 0 0 1 (\0.1) 0 1 (\0.1)
Pneumonia aspiration 1 (\0.1) 0 0 0 1 (\0.1)
CHF, Congestive heart failure; COPD, chronic obstructive pulmonary disease; E/100PY, events per 100 patient-years of total adalimumab
exposure; MI, myocardial infarction; PY, patient-year; TEAE, treatment-emergent adverse event.
*Not coded 1 event (\0.1 E/100PY) in #1 y total exposure category.
yIncludes death and sudden death.
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